Voya Investment Management LLC Lowers Position in Edwards Lifesciences Corporation $EW

Voya Investment Management LLC trimmed its stake in Edwards Lifesciences Corporation (NYSE:EW) by 29.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 946,537 shares of the medical research company’s stock after selling 389,401 shares during the quarter. Voya Investment Management LLC owned about 0.16% of Edwards Lifesciences worth $68,605,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its holdings in Edwards Lifesciences by 0.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock valued at $2,170,000 after purchasing an additional 145 shares during the period. Dynamic Advisor Solutions LLC lifted its position in Edwards Lifesciences by 2.4% during the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company’s stock valued at $1,124,000 after buying an additional 370 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Edwards Lifesciences by 13.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company’s stock valued at $5,582,000 after buying an additional 9,188 shares in the last quarter. United Asset Strategies Inc. lifted its position in Edwards Lifesciences by 10.4% during the first quarter. United Asset Strategies Inc. now owns 185,571 shares of the medical research company’s stock valued at $13,450,000 after buying an additional 17,412 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its position in Edwards Lifesciences by 390.7% during the first quarter. Farther Finance Advisors LLC now owns 8,808 shares of the medical research company’s stock valued at $633,000 after buying an additional 7,013 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on EW. Truist Financial lifted their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a “hold” rating in a research report on Friday, July 25th. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. Wall Street Zen cut shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday. JPMorgan Chase & Co. lifted their price target on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, July 25th. Finally, Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $86.26.

Edwards Lifesciences Trading Down 0.7%

NYSE EW opened at $77.50 on Friday. The company’s fifty day simple moving average is $78.92 and its 200-day simple moving average is $75.39. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock has a market cap of $45.50 billion, a P/E ratio of 11.15, a PEG ratio of 3.76 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the previous year, the company posted $0.70 earnings per share. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,014 shares of company stock worth $1,698,844 over the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.